ACADIA PHARMACEUTICALS INC. Selling, General and Administrative Expense
ACADIA PHARMACEUTICALS INC. (ACAD) reported Selling, General and Administrative Expense of $160.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $160.25M, a 20.03% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $171.02M, a 35.33% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $155.62M, a 19.63% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $133.40M, a 0.08% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2025 was $548.89M, a 12.38% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2024 was $488.43M, a 20.14% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2023 was $406.56M, a 10.15% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2022 was $369.09M, a 6.80% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $160.25M 10-Q · filed 2026-08-05 | $331.27M 10-Q · filed 2026-08-05 | $486.89M derived: sum of 3 quarters · filed 2026-08-05 | $620.29M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $171.02M 10-Q · filed 2026-05-07 | $326.63M derived: sum of 2 quarters · filed 2026-05-07 | $460.04M derived: sum of 3 quarters · filed 2026-05-07 | $593.54M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $155.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $289.02M derived: sum of 2 quarters · filed 2026-02-26 | $422.52M derived: sum of 3 quarters · filed 2026-08-05 | $548.89M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $133.40M 10-Q · filed 2025-11-06 | $266.91M derived: sum of 2 quarters · filed 2026-08-05 | $393.28M 10-Q · filed 2025-11-06 | $523.36M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $133.51M 10-Q · filed 2026-08-05 | $259.88M 10-Q · filed 2026-08-05 | $389.96M derived: sum of 3 quarters · filed 2026-08-05 | $523.25M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $126.37M 10-Q · filed 2026-05-07 | $256.45M derived: sum of 2 quarters · filed 2026-05-07 | $389.74M derived: sum of 3 quarters · filed 2026-05-07 | $506.81M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $130.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $263.37M derived: sum of 2 quarters · filed 2026-02-26 | $380.44M derived: sum of 3 quarters · filed 2026-02-26 | $488.43M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $133.29M 10-Q · filed 2025-11-06 | $250.36M derived: sum of 2 quarters · filed 2025-11-06 | $358.35M 10-Q · filed 2025-11-06 | $469.81M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $117.06M 10-Q · filed 2025-08-07 | $225.05M 10-Q · filed 2025-08-07 | $336.52M derived: sum of 3 quarters · filed 2026-02-26 | $434.41M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $107.99M 10-Q · filed 2025-05-08 | $219.46M derived: sum of 2 quarters · filed 2026-02-26 | $317.35M derived: sum of 3 quarters · filed 2026-02-26 | $413.31M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $111.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $209.35M derived: sum of 2 quarters · filed 2026-02-26 | $305.32M derived: sum of 3 quarters · filed 2026-02-26 | $406.56M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $97.89M 10-Q · filed 2024-11-07 | $193.86M derived: sum of 2 quarters · filed 2024-11-07 | $295.09M 10-Q · filed 2024-11-07 | $399.50M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $95.97M 10-Q · filed 2024-08-07 | $197.20M 10-Q · filed 2024-08-07 | $301.61M derived: sum of 3 quarters · filed 2025-02-27 | $379.71M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $101.23M 10-Q · filed 2024-05-09 | $205.64M derived: sum of 2 quarters · filed 2025-02-27 | $283.75M derived: sum of 3 quarters · filed 2025-02-27 | $373.65M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $104.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $182.51M derived: sum of 2 quarters · filed 2025-02-27 | $272.41M derived: sum of 3 quarters · filed 2025-02-27 | $369.09M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $78.11M 10-Q · filed 2023-11-03 | $168.01M derived: sum of 2 quarters · filed 2023-11-03 | $264.69M 10-Q · filed 2023-11-03 | $370.60M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-06-30 | $89.90M 10-Q · filed 2023-08-03 | $186.58M 10-Q · filed 2023-08-03 | $292.49M derived: sum of 3 quarters · filed 2024-02-28 | $374.16M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-03-31 | $96.68M 10-Q · filed 2023-05-08 | $202.59M derived: sum of 2 quarters · filed 2024-02-28 | $284.26M derived: sum of 3 quarters · filed 2024-02-28 | $381.05M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2021-12-31 | $105.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $187.58M derived: sum of 2 quarters · filed 2024-02-28 | $284.37M derived: sum of 3 quarters · filed 2024-02-28 | $396.03M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $81.67M 10-Q · filed 2022-11-03 | $178.46M derived: sum of 2 quarters · filed 2022-11-03 | $290.12M 10-Q · filed 2022-11-03 | $410.87M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $96.79M 10-Q · filed 2022-08-09 | $208.45M 10-Q · filed 2022-08-09 | $329.20M derived: sum of 3 quarters · filed 2023-02-28 | $410.79M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $111.66M 10-Q · filed 2022-05-05 | $232.41M derived: sum of 2 quarters · filed 2023-02-28 | $314.00M derived: sum of 3 quarters · filed 2023-02-28 | $398.35M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $120.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $202.34M derived: sum of 2 quarters · filed 2023-02-28 | $286.69M derived: sum of 3 quarters · filed 2023-02-28 | $388.66M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $81.59M 10-Q · filed 2021-11-09 | $165.94M derived: sum of 2 quarters · filed 2021-11-09 | $267.91M 10-Q · filed 2021-11-09 | $359.78M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $84.34M 10-Q · filed 2021-08-05 | $186.32M 10-Q · filed 2021-08-05 | $278.19M derived: sum of 3 quarters · filed 2022-03-01 | $350.88M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $101.97M 10-Q · filed 2021-05-06 | $193.84M derived: sum of 2 quarters · filed 2022-03-01 | $266.54M derived: sum of 3 quarters · filed 2022-03-01 | $334.52M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $91.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $164.57M derived: sum of 2 quarters · filed 2022-03-01 | $232.55M derived: sum of 3 quarters · filed 2022-03-01 | $325.64M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $72.70M 10-Q · filed 2020-11-04 | $140.68M derived: sum of 2 quarters · filed 2020-11-04 | $233.77M 10-Q · filed 2020-11-04 | $308.04M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $67.98M 10-Q · filed 2020-08-06 | $161.07M 10-Q · filed 2020-08-06 | $235.34M derived: sum of 3 quarters · filed 2021-02-25 | $296.43M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $93.09M 10-Q · filed 2020-05-08 | $167.36M derived: sum of 2 quarters · filed 2021-02-25 | $228.45M derived: sum of 3 quarters · filed 2021-02-25 | $297.92M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $74.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $135.36M derived: sum of 2 quarters · filed 2021-02-25 | $204.83M derived: sum of 3 quarters · filed 2021-02-25 | $265.76M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $61.09M 10-Q · filed 2019-10-31 | $130.56M derived: sum of 2 quarters · filed 2019-10-31 | $191.49M 10-Q · filed 2019-10-31 | $258.18M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $69.47M 10-Q · filed 2019-08-01 | $130.40M 10-Q · filed 2019-08-01 | $197.09M derived: sum of 3 quarters · filed 2020-02-27 | $258.68M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $60.93M 10-Q · filed 2019-05-02 | $127.61M derived: sum of 2 quarters · filed 2020-02-27 | $189.20M derived: sum of 3 quarters · filed 2020-02-27 | $250.33M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $66.69M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $128.28M derived: sum of 2 quarters · filed 2020-02-27 | $189.40M derived: sum of 3 quarters · filed 2020-02-27 | $255.06M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $61.59M 10-Q · filed 2018-11-06 | $62.26M 10-Q · filed 2017-11-07 | $122.71M derived: sum of 2 quarters · filed 2018-11-06 | $188.37M 10-Q · filed 2018-11-06 | $189.52M 10-Q · filed 2017-11-07 | $246.04M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $61.13M 10-Q · filed 2018-08-08 | $61.52M 10-Q · filed 2017-08-08 | $126.78M 10-Q · filed 2018-08-08 | $127.27M 10-Q · filed 2017-08-08 | $184.45M derived: sum of 3 quarters · filed 2019-02-27 | $234.98M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $65.66M 10-Q · filed 2018-05-04 | $65.75M 10-Q · filed 2017-05-09 | $123.32M derived: sum of 2 quarters · filed 2019-02-27 | $173.86M derived: sum of 3 quarters · filed 2019-02-27 | $224.63M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $57.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $108.20M derived: sum of 2 quarters · filed 2019-02-27 | $158.97M derived: sum of 3 quarters · filed 2019-02-27 | $186.46M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $50.53M 10-Q · filed 2017-11-07 | $101.30M derived: sum of 2 quarters · filed 2017-11-07 | $128.79M 10-Q · filed 2017-11-07 | $151.41M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $50.77M 10-Q · filed 2017-08-08 | $78.26M 10-Q · filed 2017-08-08 | $100.88M derived: sum of 3 quarters · filed 2018-02-27 | $121.18M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $27.49M 10-Q · filed 2017-05-09 | $50.11M derived: sum of 2 quarters · filed 2018-02-27 | $70.42M derived: sum of 3 quarters · filed 2018-02-27 | $91.53M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $22.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $42.92M derived: sum of 2 quarters · filed 2018-02-27 | $64.04M derived: sum of 3 quarters · filed 2018-02-27 | $88.30M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $20.31M 10-Q · filed 2016-11-07 | $41.43M derived: sum of 2 quarters · filed 2016-11-07 | $65.69M 10-Q · filed 2016-11-07 | ||||
| 2015-06-30 | $21.12M 10-Q · filed 2016-08-04 | $45.38M 10-Q · filed 2016-08-04 | |||||
| 2014-12-31 | $32.75M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |